Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 27, 494–495 (1 June 2009) | doi:10.1038/nbt0609-494b
Ariad's NF|[kappa]|B patent claims shot down on appeal
Abstract
On April 3, a federal appeals court ruled in favor of Eli Lilly in Indianapolis, Indiana, capping a seven-year legal fight with Ariad Pharmaceuticals over its patent claims surrounding nuclear factor kappa B (NFκB). The case has embroiled big pharma, several prominent biotech companies and even Nobel Prize winners as courtroom witnesses in a high-stakes tussle over the commercial reach of patents with especially broad claims.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
